[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Tr…

Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ...
The Tech Edvocate

The AI Revolution: 9 Platforms Quietly Reshaping Drug Discovery Forever

Spread the love“`html The pharmaceutical industry, traditionally a marathon of painstaking research and development, is in ...
Nature

Computational Drug Repurposing in the Era of Multimodal Data and Artificial Intelligence

Drug repurposing — the identification of new therapeutic indications for approved drugs or clinical-stage candidates — offers one of the most efficient strategies to deliver new treatments to patients ...
Business Wire

AI Detection and Repurposed Drugs Signal New Era in Food Allergy Research at Food Allergy Fund Summit

NEW YORK--(BUSINESS WIRE)--The Food Allergy Fund (FAF) today convened scientists, investors, policymakers, and advocates at its annual Summit in New York City, unveiling advances that mark a pivotal ...
Medical Xpress

Repurposed drugs move through late-stage trials at up to 90% lower cost

Universities and hospitals are repurposing existing drugs through late-stage trials with funded costs up to 90% lower than those in the pharmaceutical industry. This "hidden" research system, which ...
FiercePharma

FDA floats possible approach to repurpose approved drugs under new uses

The FDA is looking to get thrifty with its approved drugs. Through a newly proposed repurposing initiative, the agency hopes to help address unmet medical needs by finding new uses for ...
Morningstar

N-Zyme Biomedical Applauds FDA's Newly Announced Initiatives Supporting Drug Repurposing for Unmet Medical Needs

Clinical-stage biotechnology company supports efforts to advance therapies addressing significant unmet clinical needs NEWARK, DE / ACCESS Newswire / May 13, 2026 / N-Zyme Biomedical, a clinical-stage ...
RAPS

Drug repurposing: Stakeholders say FDA should act within its authority, avoid disincentives

Patient and healthcare industry stakeholders told the US Food and Drug Administration (FDA) that while there are significant opportunities to repurpose existing drugs, the agency should ensure any new ...